thiazolidinedion
tzd
potent
insulin
sensit
act
nuclear
receptor
peroxisom
proliferatoractiv
highli
effect
oral
medic
type
diabet
howev
uniqu
benefit
shadow
risk
fluid
retent
weight
gain
bone
loss
congest
heart
failur
rais
question
whether
possibl
build
safer
gener
drug
evok
fewer
side
effect
preserv
insulinsensit
potenti
recent
studi
support
continu
physiolog
therapeut
relev
pathway
also
provid
opportun
develop
newer
class
molecul
reduc
elimin
advers
effect
review
highlight
key
advanc
understand
signal
energi
homeostasi
metabol
diseas
also
provid
new
explan
advers
event
link
tzdbase
therapi
ppar
member
nuclear
receptor
superfamili
ligandinduc
transcript
factor
mammal
three
ppar
also
call
also
call
also
call
bind
pparrespons
regulatori
element
oblig
heterodim
retinoid
x
receptor
rxr
ppar
control
express
network
gene
involv
adipogenesi
lipid
metabol
inflamm
mainten
metabol
homeostasi
similar
typic
nuclear
receptor
ppar
compris
distinct
function
domain
includ
ntermin
transactiv
domain
highli
conserv
dnabind
domain
dbd
ctermin
ligandbind
domain
lbd
contain
liganddepend
transactiv
function
domain
potenti
target
modul
ppar
signal
cascad
although
known
receptor
common
dietari
fat
oleic
linol
linolen
acid
ppar
also
bind
respond
divers
lipid
metabolit
includ
prostaglandin
acid
collect
oxid
phospholipid
ligand
bind
induc
conform
chang
receptor
allow
differenti
recruit
cofactor
subsequ
modul
ppar
activ
despit
mani
similar
ppar
isoform
uniqu
function
vivo
probabl
distinct
tissu
distribut
differenti
respons
distinct
ligand
inher
differ
biochem
properti
first
ppar
identifi
express
predominantli
liver
heart
brown
adipos
tissu
bat
major
activ
fatti
acid
oxid
pathway
target
hypolipidem
fibrat
drug
although
also
call
commonli
refer
share
similar
function
ubiquit
express
crucial
role
fatti
acid
oxid
key
metabol
tissu
skelet
muscl
liver
heart
highli
express
white
adipos
tissu
wat
bat
master
regul
adipogenesi
well
potent
modul
wholebodi
lipid
metabol
insulin
sensit
altern
splice
differenti
promot
usag
exist
two
isoform
latter
contain
addit
amino
acid
n
terminu
wherea
express
mani
tissu
express
restrict
adipos
tissu
physiolog
condit
induc
tissu
highfat
diet
hfd
although
three
ppar
strongli
implic
metabol
syndrom
aim
review
focu
highlight
recent
find
shed
light
onto
signal
pathway
renew
interest
therapeut
potenti
treatment
type
diabet
even
though
fatti
acid
deriv
bind
activ
identif
specif
endogen
ligand
difficult
thu
specif
mode
action
relat
fatti
acid
metabolit
clearli
defin
contrast
synthet
ligand
tzd
potent
activ
robust
insulinsensit
activ
consequ
highli
effect
oral
medic
use
treatment
difficulttomanag
type
diabet
chronic
activ
includ
weight
gain
fluid
retent
osteoporosi
metaanalys
clinic
trial
implic
tzd
rosiglitazon
avandia
increas
risk
congest
heart
failur
myocardi
infarct
cardiovascular
diseas
allcaus
mortal
lead
tightli
restrict
access
unit
state
recommend
market
withdraw
europ
sever
jurisdict
pioglitazon
acto
anoth
tzd
seem
impart
cardiovascular
risk
rosiglitazon
inde
larg
placebocontrol
clinic
trial
indic
modest
reduct
major
cardiovascular
event
peopl
highrisk
diabet
receiv
pioglitazon
period
howev
safeti
concern
also
rais
pioglitazon
relat
congest
heart
failur
bladder
cancer
latter
lead
safeti
warn
drug
withdraw
part
europ
accordingli
understand
differ
tzd
trigger
specif
side
effect
well
altern
rout
activ
potenti
lead
new
improv
therapi
type
diabet
recent
part
power
new
technolog
box
much
progress
made
understand
signal
regul
tissuespecif
role
mani
advanc
reveal
new
insight
mechan
underli
insulin
sensit
well
associ
side
effect
provid
opportun
develop
newer
class
molecul
reduc
elimin
advers
effect
associ
tzd
appli
genomewid
analys
studi
regul
signal
recent
advanc
highthroughput
technolog
nextgener
sequenc
method
allow
investig
genomewid
transcript
regul
unbias
manner
provid
abund
inform
regard
gene
express
cisact
element
transact
factor
epigenet
statu
chromatin
structur
genom
studi
reveal
comprehens
bindingsit
distribut
adipocyt
macrophag
coloc
frequenc
transcript
factor
cebp
compar
histon
modif
profil
adipocyt
macrophag
chromatin
architectur
chang
adipogenesi
notabl
analysi
data
obtain
use
chromatin
immunoprecipit
combin
nextgener
sequenc
chipseq
context
human
adipocyt
show
bind
site
rare
promot
region
gene
account
genomewid
site
intron
intergen
enhanc
compris
major
bind
site
interestingli
although
promoterloc
bind
site
rare
gene
robustli
tzd
respons
addit
dnase
hypersensit
site
sequenc
dnaseseq
reveal
target
site
present
access
open
chromatin
structur
dna
bind
adipogenesi
indic
frequent
though
mandatori
cooper
action
earli
adipogen
transcript
factor
cebp
ad
anoth
layer
transcript
control
cytosin
hydroxymethyl
also
particip
enhanc
function
adipogenesi
collect
know
respons
network
extrem
complex
distinctli
regul
cell
typespecif
manner
howev
mani
question
remain
answer
develop
comprehens
understand
signal
coregul
involv
determin
celltyp
specif
chang
epigenom
chromatin
structur
affect
transcript
outcom
distal
regulatori
element
enhanc
control
activ
promot
although
individu
genom
approach
provid
highli
inform
specif
answer
combin
highthroughput
sequenc
applic
data
integr
necessari
comprehens
understand
transcript
event
unbias
genomewid
manner
complex
biolog
process
transcript
factor
regul
signal
must
understood
specif
pattern
associ
target
dna
process
posit
neg
regul
proxim
promot
addit
dynam
point
view
recruit
tissu
specif
coactiv
corepressor
need
establish
fulli
understand
dynam
chromatin
modif
gene
control
origin
describ
factor
induc
adipocyt
differenti
best
known
role
regul
adipogen
lipogen
pathway
fig
gener
mous
complet
devoid
adipos
tissu
firmli
establish
master
regul
adipocyt
differenti
recent
dynam
adipocyt
progenitor
popul
identifi
within
wat
perivascular
nich
whose
express
suggest
may
play
part
adipocyt
self
renew
also
requir
matur
adipocyt
function
reveal
find
adipocyt
surviv
day
select
ablat
matur
adipocyt
mice
addit
role
adipocyt
differenti
lipid
metabol
also
crucial
control
gene
network
involv
glucos
homeostasi
includ
increas
express
glucos
transport
type
ccblassoci
protein
cap
moreov
control
express
numer
factor
secret
adipos
tissu
adiponectin
resistin
leptin
tumor
necrosi
also
influenc
insulin
sensit
consid
factor
probabl
act
distinct
signal
pathway
differ
although
overlap
tissu
target
sever
differ
mechan
may
involv
achiev
insulinsensit
effect
exampl
factor
might
act
inflamm
hepat
glucos
output
adiponectin
feed
behavior
leptin
physiolog
pathway
may
complement
although
pharmacolog
increas
one
pathway
could
suffici
achiev
therapeut
benefit
none
factor
move
advanc
human
trial
howev
clearli
illustr
promis
multipl
potenti
safe
rout
therapeut
intervent
consist
central
role
adipogenesi
insulin
sensit
human
dominantneg
mutat
singl
allel
pparg
partial
lipodystrophi
insulin
resist
discoveri
tzd
known
potent
adipogen
antidiabet
effect
agonist
solidifi
import
insulin
sensit
prompt
numer
extens
studi
nuclear
receptor
thu
despit
mani
caveat
directli
target
remain
gold
standard
treat
metabol
diseas
abil
control
express
adiposesecret
factor
adiponectin
led
search
addit
regulatori
factor
fig
result
identif
two
member
fibroblast
growth
factor
famili
act
local
adipos
tissu
promot
insulin
sensit
respons
hfd
origin
found
induc
liver
respons
fast
regul
carbohydr
lipid
metabol
subsequ
reveal
induc
wat
hfd
agonist
unexpectedli
wherea
hepat
circul
hormon
adipos
circul
instead
act
autocrin
fashion
local
transduc
signal
enhanc
adipogenesi
unabl
store
fat
mice
reduc
adipos
decreas
express
target
gene
wat
moreov
mice
resist
insulinsensit
effect
tzd
well
associ
weight
gain
fluid
retent
implic
import
mediat
antidiabet
action
neg
side
effect
tzd
notabl
knockout
mice
increas
sumoyl
discuss
detail
reduc
transcript
activ
taken
togeth
find
reveal
fed
state
induc
work
local
adipos
tissu
amplifi
activ
promot
insulin
sensit
recent
found
prototyp
fgf
famili
protein
also
regul
highli
induc
viscer
adipos
tissu
respons
hfd
treatment
tzd
three
altern
gene
promot
isoform
show
diet
tzd
induc
although
implic
divers
rang
physiolog
process
knockout
mice
show
phenotyp
standard
laboratori
condit
led
longheld
assumpt
dispens
strikingli
howev
place
hfd
knockout
mice
develop
crippl
disabl
fat
fibrosi
structur
restrict
adipos
expans
result
aggress
diabet
phenotyp
moreov
hfd
withdraw
adipos
tissu
mice
properli
contract
lead
mark
fat
necrosi
structur
fragment
fat
pad
collect
concurr
sever
patholog
indic
key
role
signal
axi
adapt
adipos
remodel
maintain
metabol
homeostasi
cycl
feast
famin
work
autocrin
manner
paracrin
manner
act
local
adipos
tissu
mediat
physiolog
pharmacolog
action
studi
need
elucid
rel
role
two
fgf
regul
nevertheless
newli
identifi
signal
pathway
identifi
fgf
import
new
mediat
benefici
effect
tzd
repres
paradigm
shift
signal
hfd
drug
act
sensor
turn
direct
product
local
act
factor
fgf
control
energi
homeostasi
fig
case
pharmacolog
administr
protein
mice
result
mark
bone
loss
potenti
limit
use
therapeut
clear
understand
two
fgf
signal
pathway
well
compon
signal
cascad
crucial
dissoci
specif
mechan
respons
improv
insulin
sensit
involv
caus
advers
side
effect
associ
tzd
adipos
tissu
highli
express
tissu
notabl
gene
express
chang
respons
treatment
agonist
therefor
insulinsensit
effect
well
certain
neg
side
effect
tzd
gener
attribut
adiposespecif
activ
adipos
tissu
upregul
gene
involv
glucos
uptak
also
control
express
adipocytesecret
factor
adiponectin
commun
organ
affect
wholebodi
insulin
sensit
furthermor
high
concentr
circul
fatti
acid
posit
correl
insulin
resist
enhanc
uptak
sequestr
fatti
acid
adipos
tissu
activ
thought
amelior
insulin
resist
postul
increas
uptak
fatti
acid
enhanc
adipogen
capac
wat
elicit
activ
also
respons
tzdassoci
weight
gain
howev
select
activ
adipocyt
mice
suffici
caus
wholebodi
insulin
sensit
without
increas
weight
find
rais
possibl
adipos
tissu
might
suffici
insulinsensit
effect
tzd
side
effect
weight
gain
convers
fact
express
albeit
lower
level
varieti
nonadipos
tissu
tzd
improv
insulin
sensit
lipodystroph
fatless
mice
suggest
tissu
may
also
direct
target
contribut
insulinsensit
effect
tzd
well
unwant
side
effect
experi
tissuespecif
knockout
crucial
help
dissect
rel
contribut
activ
insulin
sensit
differ
tissu
mice
adiposespecif
ablat
show
insulin
resist
adipos
tissu
liver
skelet
muscl
mice
tzd
improv
insulin
sensit
skelet
muscl
liver
adipos
tissu
indic
direct
action
tzd
skelet
muscl
liver
well
adipos
tissu
regard
two
group
independ
examin
mice
target
ablat
skelet
muscl
one
studi
older
mice
lack
skeletalmuscl
result
sever
insulin
resist
skelet
muscl
mice
unrespons
tzd
treatment
indic
role
skeletalmuscl
action
tzd
second
studi
younger
mice
target
muscl
defici
develop
skeletalmuscl
insulin
resist
remain
respons
tzd
treatment
interestingli
mice
develop
excess
adipos
hepat
insulin
resist
suggest
insulinsensit
effect
tzd
muscl
indirect
age
depend
skeletalmuscl
may
role
regul
wholebodi
insulin
sensit
perhap
tissu
crosstalk
although
investig
help
resolv
appar
agedepend
differ
clear
skelet
muscl
play
part
tzdinduc
insulin
sensit
liver
also
propos
site
tzd
action
howev
effect
agon
liver
remain
debat
studi
show
promot
hepat
steatosi
upregul
gene
involv
lipid
uptak
storag
other
show
prevent
hepat
steatosi
fibrosi
possibl
sequest
fatti
acid
adipos
tissu
prevent
hepat
stellat
cell
activ
treatment
agonist
also
decreas
express
gene
involv
gluconeogenesi
liverspecif
disrupt
mice
result
increas
adipos
hyperlipidemia
insulin
resist
yet
mice
remain
respons
tzd
treatment
howev
lipodystroph
background
liverspecif
ablat
render
mice
resist
tzd
treatment
indic
absenc
adipos
tissu
liver
becom
major
site
tzd
action
also
express
pancreat
beta
cell
induc
express
key
gene
involv
glucosestimul
insulin
secret
gsi
tzd
shown
enhanc
gsi
insulinresist
rodent
human
howev
result
vivo
studi
conflict
one
studi
show
alter
betacel
mass
chang
glucos
homeostasi
mice
lack
beta
cell
recent
studi
show
loss
whole
pancrea
result
hyperglycemia
impair
gsi
investig
requir
determin
precis
role
pancreat
beta
cell
contribut
mediat
insulinsensit
effect
tzd
taken
togeth
studi
reveal
tzd
act
sever
key
metabol
organ
exert
insulinsensit
effect
also
import
role
variou
immun
cell
studi
focus
role
antigenpres
myeloid
dendrit
cell
macrophag
dendrit
cell
regul
lipid
metabol
transport
well
variou
process
includ
antigen
uptak
matur
activ
migrat
cytokin
product
antigen
present
macrophag
implic
antiinflamm
lipid
metabol
mice
lack
macrophag
prone
wholebodi
insulin
resist
furthermor
mice
impair
matur
antiinflammatori
macrophag
reciproc
inflammatori
gene
network
wildtyp
proinflammatori
macrophag
potent
inhibit
tzd
treatment
regard
differenti
local
distinct
set
coregul
specif
epigenet
modif
collect
influenc
celland
tissuespecif
function
emerg
technolog
advanc
provid
new
method
identifi
epigenom
process
interrog
differ
tissu
cell
type
genomewid
scale
help
uncov
tissuespecif
function
box
notabl
although
antiinflammatori
tissueresid
regulatori
reg
cell
wide
distribut
throughout
bodi
viscer
adipos
tissu
uniqu
express
high
level
contrast
reg
cell
adipos
depot
posit
rel
number
reg
cell
markedli
reduc
obes
insulinresist
state
furthermor
reg
cellspecif
knockout
reduc
respons
insulin
sensit
also
exert
antiinflammatori
role
arteri
wall
reveal
studi
lowdens
lipoprotein
receptornul
mice
much
work
need
done
explor
role
reg
cell
macrophag
type
immun
cell
better
elucid
molecular
connect
inflamm
lipid
metabol
addit
insulinsensit
benefit
tzd
import
identifi
tissu
contribut
side
effect
weight
gain
fluid
retent
bone
loss
heart
problem
although
tzdinduc
weight
gain
attribut
activ
adipos
tissu
studi
mice
human
suggest
central
role
wholebodi
energi
homeostasi
although
known
neuroprotect
antiinflammatori
role
central
nervou
system
cn
two
recent
independ
report
indic
activ
brain
rather
adipos
tissu
contribut
tzdinduc
weight
gain
use
combin
pharmacolog
genet
approach
hfdfed
rodent
studi
show
control
food
intak
energi
expenditur
action
cn
requir
increas
weight
gain
associ
tzd
although
studi
suggest
increas
leptin
sensit
may
mediat
metabol
effect
addit
work
requir
defin
specif
neural
target
clarifi
balanc
central
peripher
signal
insulin
sensit
nevertheless
two
studi
strongli
suggest
action
cn
contribut
tzdinduc
weight
gain
lead
question
properti
nonbrain
penetr
tzd
although
tzd
shown
improv
pathogenesi
diabet
nephropathi
fluid
retent
associ
edema
remain
substanti
side
effect
tzd
strategi
design
elimin
aspect
signal
would
extrem
benefici
recent
studi
reveal
tzd
contribut
fluid
retent
peripher
edema
alter
sodium
water
reabsorpt
distal
collect
duct
kidney
howev
precis
mechan
tzd
exert
action
remain
debat
diverg
find
concern
role
epitheli
sodium
channel
phenomenon
besid
impact
weight
gain
reduc
fluid
retent
may
also
lower
risk
advers
cardiovascular
event
congest
heart
failur
although
express
low
level
heart
express
increas
heart
human
metabol
syndrom
studi
cardiomyocyt
mice
result
consensu
mice
cardiomyocytespecif
knockout
show
cardiac
hypertrophi
wherea
mice
overexpress
cardiomyocyt
develop
dilat
cardiomyopathi
increas
lipid
glycogen
store
disrupt
mitochondria
although
fluid
retent
may
major
contributor
neg
impact
tzd
heart
studi
need
clarifi
role
organ
anoth
report
side
effect
tzd
higher
rate
fractur
human
patient
consist
tzd
caus
bone
loss
mice
rat
simultan
decreas
bone
format
osteoblastogenesi
increas
bone
resorpt
osteoclastogenesi
shown
inhibit
osteoblast
differenti
bone
format
embryon
stem
cell
differenti
adipocyt
instead
spontan
differenti
osteoblast
wherea
tzd
inhibit
osteoblast
differenti
promot
adipogenesi
promot
osteoclast
differenti
delet
mous
hematopoiet
lineag
result
osteoclast
defici
resist
tzdstimul
bone
resorpt
find
indic
tzdinduc
bone
loss
result
bone
cellautonom
action
simultan
inhibit
osteoblastogenesi
enhanc
osteoclastogenesi
togeth
studi
reveal
tzd
act
varieti
tissu
confer
insulin
sensit
well
caus
deleteri
side
effect
fig
import
find
open
new
avenu
research
help
direct
develop
tissuespecif
compound
improv
differenti
benefici
advers
event
also
regul
posttransl
modif
includ
phosphoryl
acetyl
sumoyl
ubiquitin
repres
potenti
distinct
featur
could
exploit
cellor
tissuespecif
modul
molecul
fig
phosphoryl
within
region
mitogenactiv
protein
kinas
mapk
repress
transcript
activ
inhibit
ligand
bind
alter
cofactor
recruit
notabl
phosphoryl
site
cyclindepend
kinas
increas
activ
therefor
phosphoryl
result
differ
transcript
outcom
depend
physiolog
context
kinas
involv
vivo
studi
phosphoryl
site
discrep
indic
investig
requir
elucid
function
site
determin
rel
role
two
kinas
regul
activ
recent
found
phosphoryl
within
lbd
protein
kinas
activ
variou
proinflammatori
cytokin
whose
amount
elev
obes
notabl
phosphoryl
affect
adipogen
capac
alter
express
distinct
group
gene
aberrantli
regul
obes
accordingli
phosphoryl
increas
adipos
tissu
hfdfed
mice
invers
correl
tzdinduc
insulin
sensit
human
ligand
prevent
phosphoryl
interestingli
nontzd
compound
poor
agonist
activ
excel
antidiabet
effect
effect
block
phosphoryl
suggest
may
possibl
creat
new
ligand
block
phosphoryl
yet
lack
classic
agon
recent
compound
name
identifi
agonist
adipogen
action
vitro
studi
obes
mous
model
shown
strong
antidiabet
action
similar
elicit
tzd
without
mani
unwant
side
effect
although
poor
pharmacokinet
properti
probabl
preclud
use
human
find
provid
hope
possibl
develop
new
class
highli
target
effect
drug
preserv
strong
antidiabet
efficaci
tzd
yet
elimin
mani
unwant
side
effect
occur
due
classic
agon
target
gene
tzd
also
capabl
induc
batlik
featur
wat
contrast
wat
store
energi
form
triacylglycerol
bat
burn
energi
uncoupl
respir
mitochondria
combin
recent
evid
adult
human
metabol
activ
bat
led
intens
interest
activ
cell
therapeut
although
known
promot
bat
adipogenesi
mechan
intrins
brown
wat
remain
unclear
howev
recent
report
tzd
increas
halflif
transcript
factor
link
bat
develop
brown
wat
interestingli
full
agonist
rosiglitazon
partial
agonist
report
elicit
brown
rais
question
whether
brown
directli
link
potenc
activ
whether
browningspecif
agonist
identifi
exampl
compound
stabil
lack
full
agonist
activ
may
promis
treatment
obes
diabet
context
recent
evid
deacetyl
naddepend
deacetylas
sirtuin
promot
recruit
suggest
new
pathway
wat
brown
could
induc
anoth
layer
control
activ
involv
sumoyl
coval
attach
small
ubiquitinlik
modifi
sumo
peptid
typic
lead
repress
transcript
factor
sumoyl
region
block
transcript
activ
possibl
promot
corepressor
recruit
new
find
knockout
mice
discuss
show
increas
activ
adipocyt
prevent
sumoyl
result
feedforward
mechan
also
sumoyl
macrophag
result
recruit
promot
inflammatori
gene
thought
inhibit
transcript
prevent
clearanc
corepressor
complex
addit
shown
ubiquitin
enhanc
ligand
bind
well
exposur
adipocyt
cytokin
although
ubiquitin
acceptor
site
yet
identifi
polyubiquitin
subsequ
degrad
proteosom
consist
short
halflif
h
protein
repres
anoth
level
control
activ
aggreg
studi
demonstr
true
potenti
exploit
ligandand
signalingdepend
posttransl
modif
better
understand
natur
insulin
sensit
lead
develop
mechanist
new
class
drug
regul
although
tzd
clearli
potent
antidiabet
effect
appar
accompani
myriad
unwant
side
effect
rang
bone
fractur
heart
diseas
major
side
effect
initi
unpredict
mainli
lack
awar
complex
signal
recent
find
shed
light
intricaci
pathway
help
dissoci
benefit
advers
side
effect
tzd
multitud
signal
pathway
includ
recent
recogn
role
induc
secret
factor
open
new
opportun
drug
develop
evid
requir
insulin
sensit
deliveri
promot
insulin
sensit
suggest
two
new
biolog
approach
treat
metabol
diseas
furthermor
evid
posit
neg
effect
action
segment
differ
celland
tissuetyp
tissuetarget
tzd
could
futur
therapeut
strategi
addit
action
classic
metabol
tissu
initi
focu
previou
research
cn
emerg
potenti
new
mediat
tzdinduc
weight
gain
therefor
compound
avoid
activ
brain
may
promis
ad
complex
new
posttransl
modif
recogn
includ
phosphoryl
affect
adipogen
capac
alter
express
distinct
group
gene
abnorm
regul
obes
compound
alreadi
develop
specif
block
phosphoryl
site
seem
effect
insulin
sensit
despit
poor
classic
agonist
properti
recent
find
provid
reason
believ
possibl
develop
new
class
highli
target
effect
drug
preserv
strong
antidiabet
efficaci
tzd
yet
elimin
mani
unwant
side
effect
previous
discuss
could
achiev
varieti
way
may
ultim
includ
combin
approach
includ
target
specif
pathway
select
agon
antagon
certain
tissu
alter
specif
posttransl
modif
induc
certain
epigenet
modif
fortun
mani
idea
without
preced
develop
ligand
select
modul
nuclear
receptor
demonstr
select
estrogen
receptor
modul
agon
estrogen
receptor
achiev
one
tissu
partial
agon
even
antagon
occur
anoth
tissu
term
select
modul
concept
base
idea
structur
distinct
ligand
result
uniqu
receptorligand
conform
signatur
affin
differ
coregul
therebi
allow
discret
gene
activ
profil
within
differ
cell
tissu
type
rel
larg
ligandbind
pocket
facilit
bind
structur
divers
endogen
synthet
ligand
addit
sever
select
modul
minim
side
effect
identifi
regard
might
also
possibl
administ
tzd
conjunct
certain
epigenet
modifi
histon
deacetylas
inhibitor
altern
new
combinatori
approach
allow
peptidemedi
select
tissu
target
nuclear
receptor
may
benefici
recent
demonstr
estrogen
receptor
agonist
seen
studi
possibl
design
compound
alter
specif
posttransl
modif
prevent
unwant
side
effect
retain
antidiabet
potenc
mention
metaanalys
clinic
trial
attribut
increas
cardiovascular
risk
rosiglitazon
pioglitazon
possibl
explan
observ
pioglitazon
favor
impact
circul
lipid
notabl
decreas
triglycerid
concentr
patient
type
diabet
wherea
rosiglitazon
opposit
effect
although
mechan
underli
differ
elucid
fulli
may
explain
least
part
pioglitazon
offtarget
effect
agonist
activ
although
differenti
action
report
increas
skeletalmuscl
mitochondri
respir
evid
suggest
may
role
mix
ppar
receptor
target
regard
number
dual
agonist
develop
safeti
concern
surround
heart
failur
renal
impair
led
withdraw
agent
clinic
trial
current
one
compound
aleglitazar
equipot
agonist
phase
trial
patient
recent
acut
coronari
syndrom
type
diabet
addit
rxrselect
ligand
refer
rexinoid
select
activ
heterodim
may
also
promis
target
especi
isotyp
rxr
shown
differenti
regul
patholog
condit
obes
altern
activ
autophagi
specif
lipas
could
strategi
gener
bioactiv
lipid
ligand
also
worth
consid
benefit
advers
effect
tzd
could
result
activ
target
ampactiv
protein
kinas
ampk
benefit
may
also
deriv
chang
way
screen
therapeut
potent
longlast
compound
less
specif
less
stabl
compound
allow
rapid
clearanc
shorter
durat
action
along
appropri
dose
schedul
strategi
may
lead
develop
therapi
act
circadian
manner
mimic
physiolog
fast
feed
cycl
nevertheless
us
food
drug
administr
alreadi
demand
cardiovascular
safeti
data
class
antidiabet
agent
might
benefici
target
clinic
outcom
upfront
either
compound
identif
stage
preclin
studi
nonhuman
primat
summari
clinic
trial
experi
tzd
tabul
recent
review
drug
class
despit
substanti
progress
made
subject
still
much
clarifi
regard
signal
sever
import
question
remain
regul
adipos
tissu
rel
contribut
uniqu
overlap
function
well
transduc
insulin
sensit
adiponectin
regard
crosstalk
variou
cytokin
transcript
factor
also
exist
may
act
coordin
factor
promot
insulin
sensit
also
mechanist
normal
circul
hepat
hormon
act
local
express
adipos
tissu
investig
composit
extracellular
matrix
adipos
tissu
import
especi
consid
target
molecul
therapeut
regard
administ
mice
pharmacolog
produc
strong
antidiabet
effect
also
caus
bone
loss
although
metabol
import
signal
pathway
reveal
dietari
manipul
knockout
mous
studi
interest
see
whether
serv
pharmacolog
independ
regul
glucos
homeostasi
insulin
resist
tissuespecif
knockout
mice
crucial
reveal
almost
everi
tissu
examin
implic
aspect
tzdinduc
insulin
sensit
although
clear
adipos
tissu
central
mediat
insulinsensit
effect
rel
import
tissu
tzdmediat
insulin
sensit
well
potenti
tissu
crosstalk
need
clarifi
particularli
light
observ
individu
loss
singl
cell
tissu
type
effect
wholebodi
insulin
sensit
one
featur
may
loss
could
predispos
anim
chronic
inflamm
may
promot
insulin
resist
realiti
field
care
explor
whether
defici
rescu
increas
amount
differ
sensit
use
anoth
small
molecul
glucocorticoid
lxr
agonist
known
suppress
macrophag
inflamm
mani
fruit
area
futur
studi
anoth
intrigu
aspect
mani
recent
studi
associ
hfd
seem
requir
elicit
mani
phenotyp
possibl
one
sever
fatti
acid
ligand
produc
hfd
feed
may
mediat
compon
effect
case
import
determin
nutrit
point
view
whether
natur
molecul
could
select
trigger
differ
signal
includ
regul
fgf
activ
brain
phosphoryl
regard
shown
distinct
transcript
activ
normal
nonpatholog
condit
compar
obes
diabet
state
also
import
question
regard
posttransl
modif
exampl
phosphoryl
alter
express
distinct
subset
gene
affect
coregul
recruit
phosphoryl
occur
tissu
also
induc
hfd
addit
although
variou
posttransl
modif
identifi
clear
revers
process
factor
phosphatas
probabl
crucial
modul
activ
lastli
must
also
keep
mind
much
knowledg
signal
base
data
rodent
model
alway
translat
directli
human
highlight
question
spark
recent
find
mani
intrigu
avenu
research
open
hold
potenti
ultim
lead
newer
class
select
molecul
move
forward
develop
next
gener
therapeut
must
focu
strategi
retain
good
potent
insulinsensit
effect
current
drug
simultan
reduc
elimin
bad
associ
side
effect
recent
find
provid
insight
mechan
underli
insulinsensit
effect
well
advers
effect
suggest
new
approach
drug
design
discuss
new
strategi
probabl
involv
chang
way
screen
compound
focus
downstream
effector
insulin
sensit
target
specif
posttransl
modif
select
agon
antagon
specif
tissu
combin
approach
aid
develop
safer
yet
highli
efficaci
molecul
provid
hope
promis
futur
therapeut
multipl
role
adipos
tissu
hfd
ligand
tzd
activ
function
heterodim
maintain
metabol
homeostasi
direct
regul
gene
harbor
ppar
respons
element
ppre
involv
adipocyt
differenti
lipid
metabol
glucos
homeostasi
well
express
adipos
secret
factor
act
transduc
ccaatenhancerbind
protein
signal
transduc
activ
transcript
respect
fatti
acid
bind
protein
acbp
acylcoabind
protein
lpl
lipoprotein
lipas
cluster
differenti
pepck
phosphoenolpyruv
carboxykinas
ac
acylcoa
synthetas
gyk
glycerol
kinas
glucos
transport
phosphoinositid
kinas
insulin
receptor
substrat
respect
known
effect
activ
activ
result
benefici
effect
green
arrow
well
advers
side
effect
red
arrow
posttransl
modif
posttransl
modif
influenc
transcript
activ
protein
stabil
celland
contextdepend
manner
ac
acetyl
p
phosphoryl
cyclindepend
kinas
